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Cancer PainSir d Transmucosal administration of fentanyl products
are increasingly used for breakthrough pain [1]. As little is
known regarding the patients’ view about their accept-
ability, 75 consecutive advanced cancer patients were sur-
veyed to assess the acceptability of these delivery systems.
Patients receiving available fentanyl products were askedTable 1
ROOs (n patients) andmean values (SD) of the following items: easy of administration, modality of administration, palatability, satisfaction,
overall impression, and time for pain relief (minutes).
Easy Modality Palatability Satisfaction Overall impression Time for pain relief
OTFC (6) 1.7 (0.5) 1.5 (0.5) 2.0 (0.6) 1.5 (0.8) 1.5 (0.5) 33.1 (43.5)
FBT (19) 2.0 (0.6) 2.0 (0.7) 1.8 (0.7) 1.8 (0.8) 1.9 (0.7) 15.9 (7.3)
SLF (37) 2.1 (0.5) 2.2 (0.4) 1.8 (0.4) 2.0 (0.6) 2.1 (0.5) 16.7 (12.5)
INFS (7) 2.1 (0.4) 2.1 (0.4) 2.0 (0.6) 2.0 (0.8) 2.0 (0.8) 15.7 (13.7)
PFEN (11) 2.4 (0.5) 2.2 (0.4) 1.8 (0.4) 1.9 (0.7) 2.1 (0.5) 15.0 (13.7)
P 0.120 0.043* 0.870 0.595 0.178 0.015x
*,x Oral transmucosal fentanyl was signiﬁcantly considered to be more problematic.about ease of administration, modality of administration,
palatability, satisfaction and global impression. For patients
who were receiving nasal products, palatability was
substituted with sense of smell. Responses were rated on a
0e3 Likert scale. Rapid onset opioids (ROOs) were globally
assessed 80 times (ﬁve patients received more ROOs).
Oral transmucosal fentanyl was signiﬁcantly consid-
ered to be more problematic for modality of administra-
tion and late pain relief (P ¼ 0.043 and 0.015, respectively)
(Table 1), possibly due to the need for patient collabora-
tion, not always possible in patients with weakness. Other
fentanyl products were well accepted by patients, in
terms of ease and modality of administration, palatability
and overall impression. Data regarding these practical
aspects of administering breakthrough pain medications
have been rarely examined. In a Canadian survey, patients
expressed a willingness to try transmucosal products
(80%) or nasal products (59%) [2]. In a recent survey,
fentanyl products were given as placebo. The usual rescue
analgesic and sublingual fentanyl were rated better than
fentanyl buccal tablet and intranasal fentanyl for acces-
sibility. It was unclear what the usual rescue analgesic
was [3]. The second generation of ROOs seems to have
favourable characteristics for some practical issues. This is
a fundamental aspect regarding the use of thesemedications, as patients’ education and compliance are
the most important factors for appropriate use of these
agents [4]. Such preliminary data on a sample of patients
who accepted to be interviewed should be conﬁrmed by
studies with speciﬁc sampling and randomisation in
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